A
Angela Lamarca
Researcher at University of Manchester
Publications - 213
Citations - 4664
Angela Lamarca is an academic researcher from University of Manchester. The author has contributed to research in topics: Medicine & Internal medicine. The author has an hindex of 22, co-authored 158 publications receiving 2143 citations. Previous affiliations of Angela Lamarca include National Health Service & University College London.
Papers
More filters
Journal ArticleDOI
Cholangiocarcinoma 2020: the next horizon in mechanisms and management
Jesus M. Banales,Jesus M. Banales,Jesus M. Banales,Jose J.G. Marin,Jose J.G. Marin,Angela Lamarca,Angela Lamarca,Pedro M. Rodrigues,Shahid A. Khan,Lewis R. Roberts,Vincenzo Cardinale,Guido Carpino,Jesper B. Andersen,Chiara Braconi,Diego F. Calvisi,Maria J. Perugorria,Maria J. Perugorria,Luca Fabris,Luca Fabris,Luke Boulter,Rocio I.R. Macias,Rocio I.R. Macias,Eugenio Gaudio,Domenico Alvaro,Sergio A. Gradilone,Mario Strazzabosco,Mario Strazzabosco,Marco Marzioni,Cédric Coulouarn,Laura Fouassier,Chiara Raggi,Pietro Invernizzi,Joachim C. Mertens,Anja Moncsek,Sumera Rizvi,Julie K. Heimbach,Bas Groot Koerkamp,Jordi Bruix,Jordi Bruix,Alejandro Forner,Alejandro Forner,John Bridgewater,Juan W. Valle,Juan W. Valle,Gregory J. Gores +44 more
TL;DR: This expert Consensus Statement, endorsed by the ENS-CCA, summarizes the latest advances in CCA, including classification, genetics and treatment, and provides recommendations for CCA management and priorities across basic, translational and clinical research.
Journal ArticleDOI
New Horizons for Precision Medicine in Biliary Tract Cancers
TL;DR: A state-of-the-art update of the current status and future directions of research and therapy in advanced biliary tract cancers is described, addressing genetic drivers and molecular biology from a translational perspective.
Journal ArticleDOI
Second-line FOLFOX chemotherapy versus active symptom control for advanced biliary tract cancer (ABC-06): a phase 3, open-label, randomised, controlled trial.
Angela Lamarca,Daniel H. Palmer,Harpreet Wasan,Paul Ross,Yuk Ting Ma,Arvind Arora,Stephen Falk,Roopinder Gillmore,Jonathan Wadsley,Kinnari Patel,Alan Anthoney,Anthony Maraveyas,Timothy Iveson,Justin S. Waters,Claire Hobbs,Safia Barber,W David J Ryder,John Ramage,Linda Davies,John Bridgewater,Juan W. Valle +20 more
TL;DR: The ABC-06 clinical trial was a phase 3, open-label, randomised trial done in 20 sites with expertise in managing biliary tract cancer across the UK.
Journal ArticleDOI
Molecular targeted therapies: Ready for “prime time” in biliary tract cancer
Angela Lamarca,Angela Lamarca,Jorge Barriuso,Jorge Barriuso,Mairéad G McNamara,Mairéad G McNamara,Juan W. Valle,Juan W. Valle +7 more
TL;DR: An overview of the status of targeted therapies in biliary tract cancers is provided and detailed discussion regarding current clinical development of IDH and FGFR inhibitors is provided, with an overview of current caveats and future steps.
Journal ArticleDOI
ABC-06 | A randomised phase III, multi-centre, open-label study of active symptom control (ASC) alone or ASC with oxaliplatin / 5-FU chemotherapy (ASC+mFOLFOX) for patients (pts) with locally advanced / metastatic biliary tract cancers (ABC) previously-treated with cisplatin/gemcitabine (CisGem) chemotherapy.
Angela Lamarca,Daniel H. Palmer,Harpreet Wasan,Paul Ross,Yuk Ting Ma,Arvind Arora,Stephen Falk,Roopinder Gillmore,Jonathan Wadsley,Kinnari Patel,Alan Anthoney,Anthony Maraveyas,Justin S. Waters,Claire Hobbs,Safia Barber,David Ryder,John Ramage,Linda Davies,John Bridgewater,Juan W. Valle +19 more
TL;DR: Level A evidence supports use of CisGem as first-line chemotherapy for ABC and no robust evidence is available for second- line chemotherapy, but level B evidence is not available.